

Maria Teresa Pellecchia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5371334/publications.pdf>

Version: 2024-02-01

159
papers

6,966
citations

53794

45
h-index

76900

74
g-index

160
all docs

160
docs citations

160
times ranked

7644
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Cross-modal connectivity effects in age-related hearing loss. <i>Neurobiology of Aging</i> , 2022, 111, 1-13. | 3.1 | 3 |
| 2 | Reliability and validity of the novel Italian version of the 14-item Resilience Scale (RS-14) in adults. <i>Neurological Sciences</i> , 2022, 43, 3079-3087. | 1.9 | 4 |
| 3 | Uncovering clinical and radiological asymmetry in progressive supranuclear palsyâ€”Richardsonâ€™s syndrome. <i>Neurological Sciences</i> , 2022, , 1. | 1.9 | 1 |
| 4 | Mild Cognitive Impairment Subtypes Are Associated With Peculiar Gait Patterns in Parkinsonâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 781480. | 3.4 | 7 |
| 5 | Retinal thinning in progressive supranuclear palsy: differences with healthy controls and correlation with clinical variables. <i>Neurological Sciences</i> , 2022, 43, 4803-4809. | 1.9 | 15 |
| 6 | The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148. | 3.9 | 222 |
| 7 | Sex Differences in Parkinsonâ€™s Disease: From Bench to Bedside. <i>Brain Sciences</i> , 2022, 12, 917. | 2.3 | 16 |
| 8 | Vitamin D as a possible biomarker of mild cognitive impairment in parkinsonians. <i>Aging and Mental Health</i> , 2021, 25, 1998-2002. | 2.8 | 7 |
| 9 | The Role of VPS35 in the Pathobiology of Parkinsonâ€™s Disease. <i>Cellular and Molecular Neurobiology</i> , 2021, 41, 199-227. | 3.3 | 35 |
| 10 | Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clinical Autonomic Research</i> , 2021, 31, 157-164. | 2.5 | 22 |
| 11 | Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 82-90. | 2.2 | 2 |
| 12 | Bipolar Disorder and Parkinson's Disease: A 123I-hoflupane Dopamine Transporter SPECT Study. <i>Frontiers in Neurology</i> , 2021, 12, 652375. | 2.4 | 5 |
| 13 | Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinsonâ€™s disease. <i>Scientific Reports</i> , 2021, 11, 8936. | 3.3 | 24 |
| 14 | Neuropsychological profile of hearing-impaired patients and the effect of hearing aid on cognitive functions: an exploratory study. <i>Scientific Reports</i> , 2021, 11, 9384. | 3.3 | 18 |
| 15 | Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 124-132. | 2.2 | 22 |
| 16 | The language profile in multiple system atrophy: an exploratory study. <i>Journal of Neural Transmission</i> , 2021, 128, 1195-1203. | 2.8 | 4 |
| 17 | Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 632891. | 3.4 | 14 |
| 18 | Severe Dyskinesia After Administration of <sc>SARSâ€”CoV2 mRNA</sc> Vaccine in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2219-2219. | 3.9 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Long-Range Auditory Functional Connectivity in Hearing Loss and Rehabilitation. <i>Brain Connectivity</i> , 2021, 11, 483-492. | 1.7 | 6 |
| 20 | Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study. <i>Frontiers in Neurology</i> , 2021, 12, 711358. | 2.4 | 7 |
| 21 | Psychometric properties of the Beck Depression Inventoryâ€”II in progressive supranuclear palsy. <i>Brain and Behavior</i> , 2021, 11, e2344. | 2.2 | 11 |
| 22 | Energy expenditure, body composition and dietary habits in progressive supranuclear palsy. <i>Journal of Neurology</i> , 2021, , 1. | 3.6 | 1 |
| 23 | Female sexual dysfunction in multiple system atrophy: does it matter?. <i>Clinical Autonomic Research</i> , 2021, 31, 649-650. | 2.5 | 1 |
| 24 | Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy. <i>Scientific Reports</i> , 2021, 11, 21683. | 3.3 | 9 |
| 25 | Midbrain MRI assessments in progressive supranuclear palsy subtypes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 98-103. | 1.9 | 39 |
| 26 | Evolution of neuropsychological profile in motor subtypes of multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 67-73. | 2.2 | 23 |
| 27 | <sc><i>GBA</i>â€”Related</sc> Parkinson's Disease: Dissection of Genotypeâ€”Phenotype Correlates in a Large Italian Cohort. <i>Movement Disorders</i> , 2020, 35, 2106-2111. | 3.9 | 83 |
| 28 | Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2020, 11, 603161. | 2.4 | 8 |
| 29 | Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <sc>Movement Disorder Society</sc> Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762. | 1.5 | 31 |
| 30 | Effects of gender on cognitive and behavioral manifestations in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2020, 127, 925-934. | 2.8 | 10 |
| 31 | The role of disease duration and severity on novel clinical subtypes of Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 31-34. | 2.2 | 10 |
| 32 | Speech disorder and vocal tremor in postural instability/gait difficulty and tremor dominant subtypes of Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2020, 127, 1295-1304. | 2.8 | 18 |
| 33 | A comparison of auditory and vestibular dysfunction in Parkinson's disease and Multiple System Atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 51-57. | 2.2 | 20 |
| 34 | Subcortical atrophy and perfusion patterns in Parkinson disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 72, 49-55. | 2.2 | 12 |
| 35 | Theory of Mind in multiple system atrophy: comparison with Parkinsonâ€™s disease and healthy subjects. <i>Journal of Neural Transmission</i> , 2020, 127, 915-923. | 2.8 | 4 |
| 36 | PERK-Mediated Unfolded Protein Response Activation and Oxidative Stress in PARK20 Fibroblasts. <i>Frontiers in Neuroscience</i> , 2019, 13, 673. | 2.8 | 38 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy. PLoS ONE, 2019, 14, e0223621. | 2.5 | 12 |
| 38 | Identifying Correlations among Biomedical Data through Information Retrieval Techniques. , 2019, , . | | 5 |
| 39 | Stridor in multiple system atrophy. Neurology, 2019, 93, 630-639. | 1.1 | 86 |
| 40 | Cortical pattern of reduced perfusion in hearing loss revealed by ASLâ€MRI. Human Brain Mapping, 2019, 40, 2475-2487. | 3.6 | 17 |
| 41 | From PARK9 to SPG78: The clinical spectrum of ATP13A2 mutations. Parkinsonism and Related Disorders, 2019, 65, 272-273. | 2.2 | 10 |
| 42 | Serotonergic pathology and disease burden in the premotor and motor phase of A53T Î±-synuclein parkinsonism: a cross-sectional study. Lancet Neurology, The, 2019, 18, 748-759. | 10.2 | 70 |
| 43 | Parkinsonâ€™s disease management and impulse control disorders: current state and future perspectives. Expert Review of Neurotherapeutics, 2019, 19, 495-508. | 2.8 | 7 |
| 44 | A critique of the second consensus criteria for multiple system atrophy. Movement Disorders, 2019, 34, 975-984. | 3.9 | 73 |
| 45 | Motor, cognitive and behavioral differences in MDS PSP phenotypes. Journal of Neurology, 2019, 266, 1727-1735. | 3.6 | 30 |
| 46 | Comparing postural instability and gait disorder and akineticâ€rigid subtyping of Parkinson disease and their stability over time. European Journal of Neurology, 2019, 26, 1212-1218. | 3.3 | 17 |
| 47 | Distinctive speech signature in cerebellar and parkinsonian subtypes of multiple system atrophy. Journal of Neurology, 2019, 266, 1394-1404. | 3.6 | 29 |
| 48 | The language profile of progressive supranuclear palsy. Cortex, 2019, 115, 294-308. | 2.4 | 31 |
| 49 | Serum miR-30c-5p is a potential biomarker for multiple system atrophy. Molecular Biology Reports, 2019, 46, 1661-1666. | 2.3 | 18 |
| 50 | Alteration of endosomal trafficking is associated with early-onset parkinsonism caused by SYNJ1 mutations. Cell Death and Disease, 2018, 9, 385. | 6.3 | 48 |
| 51 | Cognitive correlates of â€œpure apathyâ€ in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 53, 101-104. | 2.2 | 27 |
| 52 | SPECT Molecular Imaging in Familial Parkinson's Disease. International Review of Neurobiology, 2018, 142, 225-260. | 2.0 | 3 |
| 53 | Theory of mind and joint action in Parkinsonâ€™s disease. Cognitive, Affective and Behavioral Neuroscience, 2018, 18, 1320-1337. | 2.0 | 4 |
| 54 | Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3588-3597. | 3.8 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neurology</i> , 2018, 265, 2602-2613. | 3.6 | 80 |
| 56 | MDS PSP criteria in real-life clinical setting: Motor and cognitive characterization of subtypes. <i>Movement Disorders</i> , 2018, 33, 1361-1365. | 3.9 | 24 |
| 57 | Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40. | 2.2 | 17 |
| 58 | Myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 103-107. | 2.1 | 10 |
| 59 | Progressive Supranuclear Palsy-Like Phenotype in a <i>GBA</i> E326K Mutation Carrier. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 444-446. | 1.5 | 14 |
| 60 | Early Ataxia and Subsequent Parkinsonism: <i>PLA2G6</i> Mutations Cause a Continuum Rather Than Three Discrete Phenotypes. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 125-128. | 1.5 | 16 |
| 61 | Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 37, 106-110. | 2.2 | 28 |
| 62 | Assessment of apathy minimising the effect of motor dysfunctions in Parkinson's disease: a validation study of the dimensional apathy scale. <i>Quality of Life Research</i> , 2017, 26, 2533-2540. | 3.1 | 22 |
| 63 | Adult-onset pure tic disorder after post-traumatic hypoxic lesions of the globus pallidus. <i>Parkinsonism and Related Disorders</i> , 2017, 34, 75-76. | 2.2 | 0 |
| 64 | The relevance of gender in Parkinson's disease: a review. <i>Journal of Neurology</i> , 2017, 264, 1583-1607. | 3.6 | 171 |
| 65 | Merging Clinical and Imaging Biomarkers to Tackle Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 652-662. | 1.5 | 6 |
| 66 | Serum IGF-1 is associated with cognitive functions in early, drug-naïve Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0186508. | 2.5 | 30 |
| 67 | Impulsive-compulsive behaviors in Parkin-associated Parkinson's disease: a case-control study. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e26-e27. | 2.2 | 0 |
| 68 | Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 137-140. | 2.2 | 62 |
| 69 | Gender and non motor fluctuations in Parkinson's disease: A prospective study. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 89-92. | 2.2 | 42 |
| 70 | Impulsive-compulsive behaviors in <i>parkin</i> -associated Parkinson disease. <i>Neurology</i> , 2016, 87, 1436-1441. | 1.1 | 61 |
| 71 | Anxiety in early Parkinson's disease: Validation of the Italian observer-rated version of the Parkinson Anxiety Scale (OR-PAS). <i>Journal of the Neurological Sciences</i> , 2016, 367, 158-161. | 0.6 | 21 |
| 72 | Caffeine consumption and the 4-year progression of de novo Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 32, 116-119. | 2.2 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment. <i>Lancet Neurology</i> , The, 2016, 15, 1063-1074. | 10.2 | 86 |
| 74 | A genome-wide association study in multiple system atrophy. <i>Neurology</i> , 2016, 87, 1591-1598. | 1.1 | 139 |
| 75 | The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. <i>European Journal of Neurology</i> , 2016, 23, 1673-1679. | 3.3 | 74 |
| 76 | Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study. <i>Journal of Neural Transmission</i> , 2016, 123, 1399-1402. | 2.8 | 36 |
| 77 | A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease. <i>Sleep</i> , 2016, 39, 405-412. | 1.1 | 73 |
| 78 | Bilirubin and Uric Acid: Two Different Anti-oxidants in Parkinson's Disease. <i>Cell Biochemistry and Biophysics</i> , 2016, 74, 91-92. | 1.8 | 0 |
| 79 | Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 371-377. | 2.8 | 9 |
| 80 | Relationship between apathy and cognitive dysfunctions in <i>de novo</i> untreated Parkinson's disease: a prospective longitudinal study. <i>European Journal of Neurology</i> , 2015, 22, 253-260. | 3.3 | 58 |
| 81 | Olfaction in Homozygous and Heterozygous <i>SYNJ1</i> Arg258Gln Mutation Carriers. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 413-416. | 1.5 | 0 |
| 82 | Neuropsychiatric disorders in Cushing's syndrome. <i>Frontiers in Neuroscience</i> , 2015, 9, 129. | 2.8 | 124 |
| 83 | Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 275-281. | 2.1 | 38 |
| 84 | Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 489-493. | 2.2 | 97 |
| 85 | Quitting smoking: An early non-motor feature of Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 216-220. | 2.2 | 19 |
| 86 | Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 373-378. | 3.9 | 41 |
| 87 | Increased bilirubin levels in <i>de novo</i> Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 954-959. | 3.3 | 29 |
| 88 | Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1219-1226. | 2.2 | 113 |
| 89 | On the relationship between side of onset and cognition in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1391-1392. | 2.2 | 2 |
| 90 | Early Cues to Detect Atypical Panthothenate Kinase-Associated Neurodegeneration. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, e78-e79. | 1.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Presence and progression of non-motor symptoms in relation to uric acid in <i>de novo</i> Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 93-98. | 3.3 | 49 |
| 92 | Uric acid relates to dopamine transporter availability in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 127-131. | 2.1 | 29 |
| 93 | Brain anatomical substrates of mirror movements in Kallmann syndrome. <i>NeuroImage</i> , 2015, 104, 52-58. | 4.2 | 10 |
| 94 | Genetic Screening for the LRRK2 R1441C and G2019S Mutations in Parkinsonian Patients from Campania. <i>Journal of Parkinson's Disease</i> , 2014, 4, 123-128. | 2.8 | 12 |
| 95 | Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. <i>Journal of Neurology</i> , 2014, 261, 2319-2328. | 3.6 | 74 |
| 96 | Pallidal stimulation in atypical pantothenate kinase-associated neurodegeneration: Six-year follow-up. <i>Movement Disorders</i> , 2014, 29, 276-277. | 3.9 | 6 |
| 97 | Evolution of mild cognitive impairment in Parkinson disease. <i>Neurology</i> , 2014, 82, 1384-1384. | 1.1 | 2 |
| 98 | The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. <i>Neurological Sciences</i> , 2014, 35, 379-383. | 1.9 | 42 |
| 99 | Do Subjective Memory Complaints Herald the Onset of Mild Cognitive Impairment in Parkinson Disease?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 276-281. | 2.3 | 64 |
| 100 | Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease. <i>European Journal of Neurology</i> , 2014, 21, 802-807. | 3.3 | 41 |
| 101 | Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: Our experience on one hundred and thirty-eight healthy subjects. <i>Clinical Otolaryngology</i> , 2014, 39, 53-57. | 1.2 | 11 |
| 102 | Comment on Szewczyk-Krolikowski et al.: The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1319-1320. | 2.2 | 5 |
| 103 | Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 2112-2118. | 3.6 | 37 |
| 104 | Postganglionic sudomotor denervation in patients with multiple system atrophy. <i>Neurology</i> , 2014, 82, 2223-2229. | 1.1 | 45 |
| 105 | Gender differences in non-motor symptoms in early Parkinson's disease: A 2-years follow-up study on previously untreated patients. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 850-854. | 2.2 | 60 |
| 106 | How does smoking affect olfaction in Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2014, 340, 215-217. | 0.6 | 13 |
| 107 | Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients?. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 772-775. | 2.2 | 32 |
| 108 | Comment on Numao et al.: Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 680-681. | 2.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Drug induced oromandibular dystonia: A case related to prolonged use of cetirizine. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 566-567. | 2.2 | 7 |
| 110 | Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 1724-1730. | 3.6 | 45 |
| 111 | Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. <i>Journal of Neurology</i> , 2013, 260, 438-444. | 3.6 | 46 |
| 112 | Early MRI findings in acquired hepatocerebral degeneration. <i>Neurological Sciences</i> , 2013, 34, 589-591. | 1.9 | 6 |
| 113 | Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease. <i>Journal of Neurology</i> , 2013, 260, 2849-2855. | 3.6 | 83 |
| 114 | The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 264-274. | 10.2 | 426 |
| 115 | Side of onset does not influence cognition in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 256-259. | 2.2 | 28 |
| 116 | Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1143-1148. | 2.2 | 3 |
| 117 | Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 14-17. | 1.9 | 158 |
| 118 | Dopaminergic Neuronal Imaging in Genetic Parkinson's Disease: Insights into Pathogenesis. <i>PLoS ONE</i> , 2013, 8, e69190. | 2.5 | 55 |
| 119 | The Heterogeneity of Early Parkinson's Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients. <i>PLoS ONE</i> , 2013, 8, e70244. | 2.5 | 150 |
| 120 | Hearing impairment in Parkinson's disease: Expanding the nonmotor phenotype. <i>Movement Disorders</i> , 2012, 27, 1530-1535. | 3.9 | 93 |
| 121 | Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. <i>Journal of Neurology</i> , 2012, 259, 1808-1813. | 3.6 | 60 |
| 122 | Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 781-787. | 2.2 | 226 |
| 123 | Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1034-1038. | 2.2 | 83 |
| 124 | Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. <i>Neurological Sciences</i> , 2012, 33, 689-694. | 1.9 | 18 |
| 125 | Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). <i>Archives of Neurology</i> , 2011, 68, 223-30. | 4.5 | 83 |
| 126 | Progression of striatal and extrastriatal degeneration in multiple system atrophy: A longitudinal diffusion-weighted MR study. <i>Movement Disorders</i> , 2011, 26, 1303-1309. | 3.9 | 47 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Is arginine test a reliable tool for differential diagnosis of multiple system atrophy?. <i>Annals of Neurology</i> , 2010, 68, 564-565. | 5.3 | 0 |
| 128 | Restless legs syndrome is a common feature of adult celiac disease. <i>Movement Disorders</i> , 2010, 25, 877-881. | 3.9 | 44 |
| 129 | Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612. | 3.9 | 205 |
| 130 | Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system. <i>Movement Disorders</i> , 2010, 25, 2621-2626. | 3.9 | 25 |
| 131 | The GH-IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features. <i>European Journal of Neurology</i> , 2010, 17, 666-671. | 3.3 | 24 |
| 132 | Impaired transmethylation potential in Parkinson's disease patients treated with L-Dopa. <i>Neuroscience Letters</i> , 2010, 468, 287-291. | 2.1 | 20 |
| 133 | Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness as presenting symptoms of PARK2. <i>Movement Disorders</i> , 2009, 24, 303-305. | 3.9 | 14 |
| 134 | Diffusion-weighted imaging in multiple system atrophy: A comparison between clinical subtypes. <i>Movement Disorders</i> , 2009, 24, 689-696. | 3.9 | 68 |
| 135 | Olfactory dysfunction in Parkinsonism caused by <i>PINK1</i> mutations. <i>Movement Disorders</i> , 2009, 24, 2350-2357. | 3.9 | 39 |
| 136 | Subclinical sensory abnormalities in unaffected <i>PINK1</i> heterozygotes. <i>Journal of Neurology</i> , 2008, 255, 1372-1377. | 3.6 | 31 |
| 137 | The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. <i>Movement Disorders</i> , 2008, 23, 190-194. | 3.9 | 11 |
| 138 | Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008, 23, 1093-1099. | 3.9 | 215 |
| 139 | The accuracy of the arginine growth hormone test in Parkinsonism. <i>Movement Disorders</i> , 2008, 23, 1331-1331. | 3.9 | 0 |
| 140 | <i>PINK1</i> heterozygous rare variants: prevalence, significance and phenotypic spectrum. <i>Human Mutation</i> , 2008, 29, 565-565. | 2.5 | 74 |
| 141 | Twenty-Four Novel Mutations in Wilson Disease Patients of Predominantly Italian Origin. <i>Genetic Testing and Molecular Biomarkers</i> , 2007, 11, 328-332. | 1.7 | 27 |
| 142 | Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: An FP-CIT SPECT study. <i>Movement Disorders</i> , 2007, 22, 559-563. | 3.9 | 46 |
| 143 | Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG). <i>Movement Disorders</i> , 2006, 21, 179-186. | 3.9 | 126 |
| 144 | Health-related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 809-815. | 3.9 | 102 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Growth Hormone Stimulation Tests in the Differential Diagnosis of Parkinson's Disease. <i>Clinical Medicine and Research</i> , 2006, 4, 322-325. | 0.8 | 13 |
| 146 | Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. <i>Clinical Endocrinology</i> , 2005, 62, 428-433. | 2.4 | 24 |
| 147 | Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. <i>European Journal of Human Genetics</i> , 2005, 13, 748-752. | 2.8 | 197 |
| 148 | The European Multiple System Atrophy-Study Group (EMSA-SG). <i>Journal of Neural Transmission</i> , 2005, 112, 1677-1686. | 2.8 | 75 |
| 149 | The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. <i>Brain</i> , 2005, 128, 1855-1860. | 7.6 | 172 |
| 150 | Physical therapy in Parkinson's disease: an open long-term rehabilitation trial. <i>Journal of Neurology</i> , 2004, 251, 595-598. | 3.6 | 49 |
| 151 | Reduced striatal [¹²³ I]FP-CIT binding in SCA2 patients without parkinsonism. <i>Annals of Neurology</i> , 2004, 55, 426-430. | 5.3 | 49 |
| 152 | Ropinirole as a Treatment of Restless Legs Syndrome in Patients on Chronic Hemodialysis. <i>Clinical Neuropharmacology</i> , 2004, 27, 178-181. | 0.7 | 84 |
| 153 | Clinical Presentation and Treatment of Wilson's Disease: A Single-Centre Experience. <i>European Neurology</i> , 2003, 50, 48-52. | 1.4 | 34 |
| 154 | Hallervorden-Spatz syndrome resembling a typical Tourette syndrome. <i>Movement Disorders</i> , 2002, 17, 618-620. | 3.9 | 32 |
| 155 | Excitatory and inhibitory mechanisms in Wilson's disease: investigation with magnetic motor cortex stimulation. <i>Journal of the Neurological Sciences</i> , 2001, 192, 35-40. | 0.6 | 12 |
| 156 | Stimulation of growth hormone release in multiple system atrophy, Parkinson's disease and idiopathic cerebellar ataxia. <i>Neurological Sciences</i> , 2001, 22, 79-80. | 1.9 | 16 |
| 157 | Unawareness of dyskinesias in Parkinson's and Huntington's diseases. <i>Neurological Sciences</i> , 2001, 22, 105-106. | 1.9 | 105 |
| 158 | Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins. <i>Molecular Brain Research</i> , 1997, 52, 307-317. | 2.3 | 32 |
| 159 | Fist-Palm Test (FiPaT): a bedside motor tool to screen for global cognitive status. <i>Neurological Sciences</i> , 0, , . | 1.9 | 0 |